Introduction
s understanding of the A structure and functions of genes expands, so does the ability to manipulate them in new forms of treatment for inherited and acquired diseases. Gene therapy has been a topic of both scientific and ethical commentary for several decades. Actual experience in clinical trials is relatively recent, dating from the late 1980s. Since the first trial of gene transfer in humans was approved in 1989, hundreds of trials have been initiated. Institutional review boards (IRBs) can thus expect to review human gene therapy clinical trials with increasing regularity. In this article, we propose a framework to assist the review of such protocols. As will become apparent, the basic principles of the ethics of research remain unchanged. Members of the IRB need not be distracted by the technical complexities of gene therapy proposals. However, certain aspects of the basic principles of research ethics review become more important in the review of gene therapy protocols. The challenge for IRBs is to recognize when new or important issues are presented, and to determine whether they are dealt with appropriately by the investigators before approving, recommending amendment, or disapproving protocols.
In previous work, we addressed the review of gene localization and identification protocols 1 and genetic diagnostic and screening studies. 2 In the present article, we provide a general description of gene therapy techniques, set out a checklist/critical path identifying issues for IRB review (Table 1) , and discuss in greater detail several points of controversy raised by this kind of research. A glossary is provided for terms that are not defined in the body of the text (Table  2) . Because a number of the issues addressed in our first two papers are relevant to gene therapy, we recommend that the three articles be read together. Table 1 . Schema for IRB Review of Gene Therapy/Gene Transfer Protocols Background and justification • Why is this disease a good candidate for gene transfer or gene therapy?
IRB
• What previous work has been done, including studies of animals and cultured cell models? Does the work demonstrate effective gene delivery? How does the proposed study relate to previous work?
• Is the disease course sufficiently predictable to allow for meaningful assessment of the results of the treatment proposed?
• What level of gene expression is presumed to be required to achieve the desired effect?
•
Given responses to the above questions, is there a sufficient justification for the investigator to proceed at this point to a clinical trial?

Research design
• What are the objectives of the proposed study (e.g., establishing feasibility or relative safety of the gene transfer, determining therapeutic effectiveness, establishing a safe dose range, demonstrating proof of principle, etc)?
• Is the goal of the study to ameliorate or cure disease or to enhance healthy individuals?
• What is the target tissue for gene transfer (e.g., bone marrow cells, skeletal muscle cells, respiratory epithelial cells, central nervous system tissue, etc.)?
• What method(s) (e.g., direct injection, inhalation, ex vivo genetic modification with injection of modified cells) and reagent(s) (e.g., vectors based on retroviruses, adenoviruses, adeno-associated viruses, herpes viruses) will be employed for gene delivery? What is the rationale for their use? Are other methods or reagents known that are more appropriate with regard to efficacy, safety, and stability?
• How will the investigator determine the proportion of cells that acquires and expresses the added DNA?
• How will the investigator determine if the product is biologically active?
stitute the direct repair of mutations. Although gene surgery is technically feasible (by a procedure termed "gene targeting"), its minimal efficiency precludes utilization in the treatment of human disorders at this time. Gene supplementation may also be used to counter the effects of an acquired disease, such as cancer. This is intended to augment nor-• Is the planned statistical treatment appropriate:
i.e., is it likely to provide valid answers to the study question?
• Gene Delivery Strategies. At this stage of development, there are three principal strategies for delivering genes to cells: ex vivo, in vivo, and micro-encapsulation. In the ex vivo approach, somatic cells that are to be genetically modified are removed, cultured, and exposed to viral or nonviral vectors or "free" nucleic acids containing the gene of interest. After transduction or insertion of the gene of interest into these cells, they are readministered to the With in vivo gene therapy, the genetically altered viral or nonviral vectors or "free" nucleic acids are administered directly to the patient, locally or systemically depending on the purpose of the genetic intervention. Local delivery dothelium, such as the coronary is appropriate where tissue is acvasculature. Local delivery into tucessible. For example, bronchosmors by direct injection is used to copy or aerosol has been used for enhance immune recognition in delivery to the lungs, insertion malignant disease. Some protocols into the portal circulation for liver require systemic delivery with uptake, local delivery to the epsome form of targeting of particuithelial surfaces of the colorectum, lar cells or organs. The exact site or the use of sophisticated catheter of introduction may be irrelevant, systems to gain access to specific provided gene expression takes components of the vascular enplace and the therapeutic molecule IRB is released and can reach the intended site of action. 4 A third approach to gene supplementation involves micro-encapsulation of gene-modified cells using devices made of a polymer envelope that are placed, for instance, within the subarachnoid or the subdural space, allowing for the slow release of therapeutic molecules to targeted areas.
Several other strategies currently under study involve the delivery of "naked" DNA (without a protein envelope) ex vivo. With micro-injection, DNA is physically injected into target cells. Another method uses calcium phosphate coprecipitated with DNA, which allows cells to take up DNA. The use of electroporation to expose cells to rapid pulses of high voltage current that create reparable holes in Table 2 . Glossary the cell membrane enables the cells to take up DNA from the surrounding medium.
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Gene Delivery Vehiclea. At this point, human gene supplementation research has most often made use of modified viruses as vectors. The viruses are engineered so that those gene sequences normally harmful to humans are deleted and the sequences that allow the viruses to integrate into the host genome are preserved. Murine retrovirus vectors have been most commonly used. These viruses transfer genes into replicating cells by using the cell's replication machinery for integration such that the viral genome is integrated into the human cell genome. An advantage of this vector is the potential for long-term expression of the gene 4 adenovirus: a virus that causes flu-like respiratory infections in humans.
adeno-associated virus: a non-infectious virus that integrates into the host genome.
coding sequence: those portions of a gene which provide the instructions for making the gene product (typically a protein).
chromosomes: subcellular bodies composed of highly condensed, double stranded DNA molecules, and containing a linear, end to end arrangement of genes.
complement: a substance, normally present in serum, that is destructive to certain bacteria and other cells.
DNA: deoxyribonucleic acid: a double stranded molecule (held together by weak bonds between base pairs of nucleotides) that encodes genetic information.
epithelium: the purely cellular avascular layer covering all of the free surfaces, cutaneous, mucous, and serous.
endothelium: a layer of flat cells lining especially blood and lymphatic vessels and the heart. ex vivo: outside of a living being.
germ line: pertaining to the cells from which the gametes (egg and sperm) are derived.
immune recognition: the process by which an organism recognizes and begins to combat an invading organism or a foreign body.
in vivo: in a living being. 7 Liposome complexes have been employed in a number of gene therapy protocols, in most cases using in vivo delivery to a local anatomical site. Liposome sacs can be filled with DNA, which is then delivered into human cells by fusing the liposomes with the recipient cells. 8 Two major advantages of this vector system are that there is no possibility for replication or recombination to form an infectious agent and that the absence of proteins reduces the risk of unwanted immune or inflammatory reactions. 9 The safety advantages of this vector system are discussed more fully below.
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Another approach under study involves a combination of in vitro and in vivo gene delivery procedures known as cell grafting. In this method, genes are transferred into cells that have been removed and that can, upon their return to the body, metabolically cooperate with cells that cannot be removed. The removable cells are harvested, cultured, and subjected to gene transfer using one of the in vitro methods described above. When the corrected cells are replaced in a living organism, they produce the desired gene products and should transmit them to the cells where they are needed.
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Researchers have generally agreed that currently there is no single vector ideal for all situations. Each of the available vectors has some advantages and disadvantages. New vectors are under development in many laboratories. 11 Research into genomic DNA-based strategies independent of the viral vector approaches, such as gene targeting and human artificial chromosome technology, is also being pursued. If successful, these strategies would have the major advantage of maintaining the integrity of the endogenous gene. Table 1 
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Schema for Review
IRBs may add other questions to those we provide. They may also refer to the questions outlined in our earlier papers. 13 These questions should be considered as supplementary to, not a replacement for, those contained in the National Institutes of Health "Points to Consider" document. 14 Given the novelty and technical complexity of many gene therapy studies, not all IRBs will have the expertise to deal with all of the issues raised. In such cases, they should consult with specialists in appropriate disciplines.
Discussion
Gene therapy protocols, whether gene marking, supplementation, or surgery, raise many ethical issues. We have chosen four for further discussion below.
Forum for Review. Review of gene therapy protocols could be accomplished using a variety of mechanisms, including local hospital or university committees, intrauniversity review, use of specialized regional or national bodies, or some combination of these.
Local review has the benefit of raising local awareness of the ethical issues and taking local community needs, values, and interests into account. It may be more effective in dealing with these needs and interests than review that must be carried out at a long distance. 15 Local review boards will be more familiar with both the investigators and the patient populations within their own institutions. On the other hand, gene therapy often generates scientifically difficult and ethically demanding questions. Because it is extremely specialized, of great public interest, and raises a number of new issues, national review has a number of advantages. It permits greater access to experts from across the country, allowing for a broader perspective and additional analytic resources. A national review committee could maintain consistency, providing standardization of requirements across the country for what may be controversial projects. It may help avoid the conflicts of interest local reviewers might face with protocols from their home institutions. 16 Unlike the local review process, national review allows for collecting results from around the country, monitoring the progress of protocols and rapidly disseminating the results. It should assist in avoiding overlap or duplication in protocols. In its recently published Guidelines on Ethical Issues in Medical Genetics and the Provision of Genetic Services, the World Health Organization recommends that protocols for human gene therapy should receive national review. 17 Under a national review structure, local IRB approval may be a prerequisite for national review. A two-step process was originally established in the United States for federally funded gene therapy research, with review first by the IRB of the local institution, and then, if this review was positive, by the Recombinant Advisory Commit tee (RAC) of the National Institutes of Health. The role of the RAC has recently been modified to include review only of vector systems that are entirely new in addition to its social policy role. In Canada, the Medical Research Council and the Royal Commission on New Reproductive Technologies both held that a two-tiered review mechanism would provide the most effective and appropriate review process for IRB these types of protocols. 18 However, there is as yet no functioning national review committee.
Where national review does not exist, regional or intra-university committees might be helpful. They could offer some of the advantages of a national review, especially if they provided greater access to specialized analytical resources. Regional review is required in some jurisdictions. In Denmark and France, for example, all human subjects research must be reviewed by regional committees; there are no local review mechanisms. 19 Where the relevant expertise in either genetics or research ethics is not available within a single institution, such as a university hospital or research institute, there may be advantages to establishing a university-wide IRB to review genetics protocols involving human subjects. The mandate of such a board does not necessarily have to pre-empt approval by a local IRB. It could offer an alternative review that, if positive, the local boards could accept or reject.
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Safety: Risks to Subjects, Risks to Society. Risks associated with gene therapy studies can be classified as risks to individuals and risks to society. As with other clinical research, the IRB has an obligation to ensure that "risks to subjects are minimized" and that "risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result." 20 A substantial problem in early gene therapy research was uncertainty regarding the nature and probability of adverse outcomes. 21 After almost a decade of experience with gene therapy, many risks are more completely characterized.
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What risks do gene therapy studies pose to research participants? No single roster of risks is applicable to all gene therapy studies. The risks posed to participants vary with the technique used to transfer the genetic material into the subject's body. As described above, a wide variety of viral and nonviral vectors is currently used in such studies. A number of the most important risks are: contamination during vector preparation; immune response; malignancy; and viral recombination, replication, and shedding.
Contamination during vector preparation. As with the preparation of any biological therapy, gene therapy carries risks that stem from inadequate control of the biological source, the production process, and the bulk and final product. 23 These risks include: transfer of an unwanted gene or genes to the subject, administration of replication competent virus, or bacterial contamination of the vector preparation. 24 The IRB has an obligation to ensure that the technical and animal data are reviewed and that every precaution has been taken to minimize risk to subjects. 25 Immune response. Certain delivery systems may trigger a significant immune response and in some cases this may interfere with treatment efficacy. For example, an attempt to transfer a "therapeutic dose" of CFTR genes in patients with cystic fibrosis seems to have been thwarted by an immune response to the adenovirus vector. 26 Current efforts are looking at ways of reducing the immunogenicity of the adenovirus itself or of suppressing the body's immune response to the virus. 27 Attempts at myoblast transfer to patients with Duchenne's muscular dystrophy may have failed for similar reasons. 28 In other cases, the immunogenicity of the vector may be turned to therapeutic advantage. Naked DNA, for example, is highly immunogenic and, as a result, it may be useful as a vaccine.
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Malignancy. Some viral vectors, including retrovirus and adeno-associated virus, permanently incorporate into the research subject's genetic material. Since this occurs in a relatively random manner (less so for adeno-associated viruses), the vector integration may disrupt important host genes, such as tumor-suppressor genes, or may activate oncogenes, in either case promoting the occurance of a malignancy. To date, no cancers related to gene therapy have been observed in the roughly 2,000 patients treated in clinical trials. 30 It is too early, however, to conclude that malignancy is not a risk associated with gene therapy. A reliable assessment of the risk of cancer will require long-term follow up of large numbers of patients. 31 Viral recombination, replication, and shedding. Great care is usually taken in the preparation of viral vectors to ensure that they are incapable of virus reproduction. Nonetheless, there remains a theoretical possibility, perhaps particularly with adenoviruses, that the vector might combine with a virus in the environment and regain the capacity to reproduce. Therefore, both persons who receive gene therapy and those with whom they are in contact (e.g., friends, family and health care workers) might be at risk of infection with virus carrying genes with powerful biological functions. 32 Experience to date indicates that the risk of a virus regaining its reproductive potential is less than was previously feared.
33
Risks to society. A number of risks to society have been suggested in the literature. Concerns regarding the effect of gene therapy on the "gene pool" may be dispensed with immediately. While it is true that any therapy directed against genetic disease may increase the frequency of diseasecausing genes, gene therapy is most often directed against recessive conditions in which affected individuals are rare relative to carriers. As a result, gene therapy will have a very small effect on allele frequencies. 34 For example, if a lethal recessive condition affects 1 in 10,000 births, then 1 in 50 in the population are carriers. If gene therapy cured the disease, after 100 generations (roughly 2,000 years) 1 in 2,500 births would be affected by the disease. 35 Other concerns are less easy to dismiss. While the use of gene therapy is currently restricted to the insertion of new genes into somatic cells, gene therapy could be used in other ways. It could be used to treat a disease once and for all by replacing the defective gene in germinal cells, thereby eliminating the transmission of disease to subsequent generations. Gene therapy could also be used to add genes that confer qualities perceived to be of benefit-to enhance humans, rather than treat disease. These possibilities are discussed in separate sections below.
Genetic Enhancement. Many would find the use of gene therapy for enhancement purposes dangerous and even objectionable. And yet our first steps along the road of somatic gene therapy could make such unwanted outcomes all too likely. Using genetic technology to promote socially desirable personal characteristics rather than to cure disease may become feasible. 36 The mere possibility of gene enhancement through genetic therapy could create normative pressure and decrease society's threshold of acceptance of diversity.
The debate on enhancement is not new and not limited to gene therapy. In our society, effective treatments tend to undergo progressive expansion in use. Prozac, which has been enormously successful in the treatment of clinical depression, now is used by some to treat a wide variety of symptoms, including low self-esteem. 37 Similarly, in vitro fertilization technology, designed to bring hope to young infertile couples, has been employed repeatedly to satisfy the reproductive desires of postmenopausal women. 38 Human growth hormone is likewise used to increase the height of apparently normal children of short stature. 39 
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Current research in the area of behavioral genetics suggests that not only well-recognized psychiatric diseases have a genetic component, but also specific personality traits, such as novelty seeking, aggressiveness, and shyness. 40 Although gene therapy to stimulate or suppress these traits may not be feasible given the complexity of such common polymorphisms, how appropriate would such interventions be if they did become feasible?
The line between treating disease and changing characteristics not associated with disease can be easily blurred, making it difficult to agree on what exactly qualifies as enhancement. 41 When does a personality trait qualify as a psychiatric disorder? And when is short stature a disability? Where is the line between using memorystimulating drugs in Alzheimer's patients and the use of similar drugs to deal with a "normal" memory loss linked to age? 42 Clear demarcations between appropriate and inappropriate uses of therapy-for example, between medical treatment and nonmedical enhancement-are often lacking in gene therapy and gene transfer studies. 43 Despite the weightiness of these concerns, it would be unjust-and contrary to U.S. regulations-for IRBs to saddle individual protocols with these slippery slope arguments. 44 But whether the pursuit of genetic enhancement runs counter to important values should be the subject of further debate. Where then is the proper forum for these issues? In the U.S., the Recombinant DNA Advisory Commission is the natural locus for these matters to be addressed. In 1996, however, RAC's scope was severely restricted, its membership was cut from 25 to 15, and the committee was nearly eliminated. 45 In Canada, the legislation recommended to provide for such a forum 46 has never been introduced. The continuing importance of affairs related to the impact of genetic interventions on society highlights the central role that RAC and like bodies in other countries must continue to play.
Interventions Affecting the Germ Line: Intentional and Unintentional
Permanent effects on the germ line may occur both accidentally and intentionally. The accidental transmission of genetic material to the germ cells could happen if the vector unintentionally transferred genetic information into the genome of germ cells. This could occur in the recipients of the gene therapy or in persons who come in contact with them. It is one of the risks that the IRB must weigh against the potential benefits of a gene therapy study.
Intentional genetic modification of the germ cells is more controversial. While significant technical problems would have to be overcome to achieve germ-line genetic intervention, work with animals has demonstrated success using a limited number of techniques.
Advantages and Disadvantages of Germ-Line Therapy. Germ-line gene therapy offers several theoretical advantages over somatic cell therapy. A gene that is added to the cells of a preimplantation embryo, for example, would be passed down to all future cells as the cells divide. This would allow the addition of the properly functioning gene to all the affected cells at once, thereby eliminating the problems of targeting, especially in conditions such as cystic fibrosis that affect many different organs and their diverse cell types. It also addresses the adequacy of gene product expression encountered in some of the somatic cell therapy research. Because they are performed at the earliest stages of human development, germ-line interventions could also avoid any irreversible damage caused by the defective gene during cell differentiation. 47 And it could assure that the patient would not pass down the defective gene to his or her descendants. To reduce the incidence of the disease in the gene pool, heterozygous carriers of the gene would also have to undergo germ-line correction of the gene, which appears highly impractical and unjustifiable at this point.
Many geneticists, ethicists, policy analysts, and legislators have expressed hesitancy about-and in many cases opposition to-deliberate manipulation of germ cells. Most written guidelines advocate a total prohibition of germ-line modification; a few have suggested continuing discussion of its technical and ethical aspects and the development of adequate safeguards. 48 Many thoughtful considerations of the ethical issues involved in germ-line interventions have appeared in the literature over the years. They range from theoretical arguments based on moral reasoning to practical appraisals of safety issues.
IRB
Principle-based argumentation focuses on the effect that germ-line manipulation will have on future generations, who will have no opportunity to consent to the changes. 49 The use of human embryos in the development of the technologies raises further consent issues. 50 The issue of consent is not only theoretical. There are practical questions concerning moral and legal responsibilities to those future generations who may be harmed by an intervention.
An argument based. on the right to be born with one's genome, or genetic patrimony, intact has been particularly strong in Europe. 51 Making heritable changes denies that right. On a broader social level, arguments have been made that the gene pool is a common possession of all humans and should not be subject to artificial, or perhaps arbitrary, manipulation. 52 
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While arguments in favor of germ-line interventions stress society's obligation's to relieve and to prevent human suffering and premature death from genetic diseases, 53 agreement on any natural demarcation between "healthy' and "unhealthy" genes may be impossible. 54 Experiences cited above with pharmacotherapy such as Prozac and human growth hormone indicate that we have not yet succeeded in making these distinctions.
Others have expressed theologically based concerns about genetic manipulation as "playing God." Increasing control over the human "product" of genetic intervention is seen as both depersonalizing and dehumanizing. These critics believe this "artificial origin" will have an effect on the ongoing content of human life. 55 "Slippery slope" claims are concerned with the possibility that once a program of "negative" eugenic engineering to avoid disease begins, application of the technology for "positive" eugenics to enhance will follow. The likelihood of this shift occurring is greater when the dividing line between negative and positive is blurred. 56 Ethical issues based upon practical considerations center around cost and safety. The justice of allocating significant health resources to an expensive intervention that has extremely limited applicability is a real concern. The number of couples who cannot use alternative technologies (prenatal diagnosis and selective termination or preimplantation diagnosis) is extremely small. Belated to the question of cost is the question of availability, and whether germ-line techniques would be available only to those who could pay for them privately. Safety questions have been the least controversial of the concerns raised. The possibility of adversely affecting not only the patients but all of their progeny creates weighty moral questions. How much knowledge is required not only about the intervention technique itself, but about the gene in question and its interactions with other genes and environmental factors, in order to judge its safety?
IRBs are unlikely to review protocols involving intentional germline manipulation for some time to come. Nonetheless, members should be aware that the techniques now being developed for somatic cell therapy will also facilitate germ-line research. These issues, as with questions of enhancement, require public discussion and education at a national level to avoid potential excesses.
